Last $103.75 USD
Change Today +6.40 / 6.57%
Volume 6.3M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

vertex pharmaceuticals inc (VRTX) Snapshot

Open
$98.12
Previous Close
$97.35
Day High
$105.53
Day Low
$97.54
52 Week High
09/19/14 - $105.53
52 Week Low
11/12/13 - $58.06
Market Cap
24.7B
Average Volume 10 Days
1.8M
EPS TTM
$-1.60
Shares Outstanding
238.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERTEX PHARMACEUTICALS INC (VRTX)

vertex pharmaceuticals inc (VRTX) Related Businessweek News

View More BusinessWeek News

vertex pharmaceuticals inc (VRTX) Details

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing other research and early-stage development programs. It markets KALYDECO to treat patients of six years of age and older with CF who have specific genetic mutations in their cystic fibrosis transmembrane conductance (CFTR) regulator gene in the United States, European Union, and Canada. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. In addition, it is developing Ivacaftor in combination with CFTR corrector compounds, which has completed Phase III development program; and evaluating VX-661, a second investigational CFTR corrector, in combination with ivacaftor in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. Further, it is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. The company sells its products principally to major and selected regional wholesalers and specialty pharmacy providers in North America, as well as government-owned and supported customers in Europe. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

1,800 Employees
Last Reported Date: 02/11/14
Founded in 1989

vertex pharmaceuticals inc (VRTX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $583.0K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $619.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $553.8K
Chief Legal Officer and Executive Vice Presid...
Total Annual Compensation: $465.0K
Compensation as of Fiscal Year 2013.

vertex pharmaceuticals inc (VRTX) Key Developments

Vertex Pharmaceuticals Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM

Vertex Pharmaceuticals Incorporated Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 08:35 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ian F. Smith, Chief Financial Officer and Executive Vice President.

Vertex Pharmaceuticals Inc. Stops Selling Incivex, Hepatitis C Drug

Vertex Pharmaceuticals Inc. has told doctors it will discontinue sales of Incivek, the hepatitis C treatment that was the first drug developed by the Boston Company. Incivek was approved by US and European regulators in 2011. More than 100,000 people globally have taken it over the past three years. But new and better treatments for hepatitis C especially the hugely successful pill Sovaldi has virtually wiped out sales of Incivek. The move was the latest in a series of steps Vertex has taken over the past year to back away from the hepatitis C market and refocus the company's efforts on treatments for cystic fibrosis, a life-threatening genetic disease that affects the lungs and digestive system.

Vertex Receives European Approval for KALYDECO(TM) (ivacaftor) in Eight Non-G551D Gating Mutations

Vertex Pharmaceuticals Incorporated announced that the European Commission has approved KALYDECO(TM) (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Today's approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012 for people with CF ages 6 and older who have the G551D mutation, which is the most common gating mutation. The eight additional gating mutations included in today's approval are: G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P and G1349D. In Europe, approximately 250 people ages 6 and older have one of these non-G551D gating mutations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $103.75 USD +6.40

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $161.44 USD -0.12
BioMarin Pharmaceutical Inc $69.85 USD +0.25
Illumina Inc $172.26 USD -5.66
Jazz Pharmaceuticals PLC $163.64 USD +0.41
Regeneron Pharmaceuticals Inc $358.92 USD -3.82
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.2x
Price/Book 21.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.